Bristol Myers Squibb Company $BMY Shares Sold by Guggenheim Capital LLC

Key Points

• Guggenheim Capital LLC has reduced its position in Bristol Myers Squibb by 7.8%, owning 667,507 shares after selling 56,169 shares, which were valued at approximately $40.71 million.
• Bristol Myers Squibb reported a quarterly earnings per share (EPS) of $1.46, exceeding analyst expectations of $1.07, with a revenue of $12.27 billion, reflecting a 0.6% increase from the previous year.
• The company announced a quarterly dividend of $0.62 per share, resulting in an annualized yield of 5.2%, although it has a payout ratio of 100%.

Guggenheim Capital LLC decreased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 7.8% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 667,507 shares of the biopharmaceutical company's stock after selling 56,169 shares during the period. Guggenheim Capital LLC's holdings in Bristol Myers Squibb were worth $40,711,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Pinney & Scofield Inc. bought a new position in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $25,000. Park Square Financial Group LLC bought a new position in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $26,000. Global Wealth Strategies & Associates increased its stake in shares of Bristol Myers Squibb by 137.5% during the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 275 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Bristol Myers Squibb during the first quarter valued at approximately $31,000. Finally, Accent Capital Management LLC bought a new stake in shares of Bristol Myers Squibb during the first quarter valued at approximately $33,000. Institutional investors own 76.41% of the company's stock.

Analyst Upgrades and Downgrades

BMY has been the subject of several analyst reports. Wall Street Zen downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price target for the company. in a research report on Tuesday, August 5th. Citigroup reduced their price target on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating for the company in a research report on Friday, August 1st. Daiwa America downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Finally, Morgan Stanley restated a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $56.38.

Bristol Myers Squibb Trading Up 0.6%

Bristol Myers Squibb stock traded up $0.29 during trading hours on Monday, hitting $47.17. The company had a trading volume of 10,685,502 shares, compared to its average volume of 10,338,380. The firm has a market cap of $96.01 billion, a P/E ratio of 19.02, a P/E/G ratio of 2.41 and a beta of 0.35. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. Bristol Myers Squibb Company has a 1 year low of $42.96 and a 1 year high of $63.33. The company has a 50-day moving average price of $47.05 and a two-hundred day moving average price of $50.70.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm had revenue of $12.27 billion during the quarter, compared to analysts' expectations of $11.32 billion. During the same quarter in the prior year, the company earned $2.07 EPS. The company's revenue was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were paid a $0.62 dividend. The ex-dividend date was Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.3%. Bristol Myers Squibb's dividend payout ratio is presently 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.